Locally/regionally advanced melanoma confers a major challenge in terms of surgical and
medical management. Surgical treatment carries the risks of surgical morbidities and …

The discovery of immunotherapy and targeted therapy has introduced new and effective
treatment options for advanced melanoma, providing therapeutic options where none …

Neoadjuvant therapy has demonstrated promise as a treatment modality in resectable
advanced‐stage melanoma. Treatment has evolved beyond chemotherapy, with the …

Simple Summary The current standard of care for locally advanced melanoma is surgery first
followed by systemic therapy. However, there is growing evidence that neoadjuvant therapy …

Patients with locoregionally advanced but surgically operable melanoma continue to carry a
high risk of relapse and death despite the best available standard management approaches …

Stage III melanoma encompasses a range of disease burdens, including microscopic foci of
metastatic melanoma in a sentinel lymph node; bulky, clinically detected lymphadenopathy; …

The treatment of malignant melanoma has drastically changed over the past decade with the
advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and …

Abstract Purpose of Review Neoadjuvant therapy in melanoma is an area of active
investigation with numerous completed and ongoing trials studying a variety of therapeutic …

Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with
or without in-transit metastases, represents approximately 15% of new melanoma diagnoses …

Introduction: The aim of this work is to discuss the role of neoadjuvant therapy in melanoma
patients, namely the potential to improve control and surgical resectability of locoregional …